Pro­tein ther­a­peu­tics biotech us­ing 'pro­tein bar­codes' in drug de­vel­op­ment se­cures new fi­nanc­ing — led by Jeff Hu­ber

Two years af­ter kick­ing things off with $5.4 mil­lion, a George Church spin­out is re­fill­ing its cof­fers to fu­el its ef­forts tack­ling pro­tein ther­a­peu­tics R&D.

Boston biotech Man­i­fold Bio an­nounced the new Se­ries A Thurs­day, led by new VC Tri­atom­ic Cap­i­tal, rais­ing $40 mil­lion to ad­vance its in­ter­nal pipeline and ex­pand its plat­form ca­pa­bil­i­ties. CEO and co-founder Gleb Kuznetsov tells End­points News that the fi­nanc­ing should last the biotech close to 2.5 years, de­pend­ing on how fast the com­pa­ny spends it.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER